Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Peking University
- Target Recruit Count
- 12
- Registration Number
- NCT02645864
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT02596256
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Apatinib for Metastatic Esophageal Cancer.
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Hangzhou Cancer Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT02544737
- Locations
- 🇨🇳
Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China
Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2016-08-02
- Target Recruit Count
- 40
- Registration Number
- NCT02537171
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- Qingdao Municipal Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02525237
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 48
- Registration Number
- NCT02510469
- Locations
- 🇨🇳
Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 48
- Registration Number
- NCT02509806
- Locations
- 🇨🇳
Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
- Conditions
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 400
- Registration Number
- NCT02493582
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 80
- Registration Number
- NCT02485015
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT02409199
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.